EYPT
Price
$14.51
Change
+$0.82 (+5.99%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
1.18B
92 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$11.45
Change
+$0.20 (+1.78%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
2.49B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EYPT vs OCUL

Header iconEYPT vs OCUL Comparison
Open Charts EYPT vs OCULBanner chart's image
EyePoint Pharmaceuticals
Price$14.51
Change+$0.82 (+5.99%)
Volume$6.85K
Capitalization1.18B
Ocular Therapeutix
Price$11.45
Change+$0.20 (+1.78%)
Volume$97.05K
Capitalization2.49B
EYPT vs OCUL Comparison Chart in %
EYPT
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EYPT vs. OCUL commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Buy and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (EYPT: $13.69 vs. OCUL: $11.25)
Brand notoriety: EYPT and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 24% vs. OCUL: 38%
Market capitalization -- EYPT: $1.18B vs. OCUL: $2.49B
EYPT [@Biotechnology] is valued at $1.18B. OCUL’s [@Biotechnology] market capitalization is $2.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, EYPT is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 5 TA indicator(s) are bullish while OCUL’s TA Score has 6 bullish TA indicator(s).

  • EYPT’s TA Score: 5 bullish, 5 bearish.
  • OCUL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than EYPT.

Price Growth

EYPT (@Biotechnology) experienced а -7.12% price change this week, while OCUL (@Biotechnology) price change was -7.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

EYPT is expected to report earnings on Mar 05, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.5B) has a higher market cap than EYPT($1.18B). EYPT YTD gains are higher at: 83.758 vs. OCUL (31.733). EYPT has higher annual earnings (EBITDA): -172.05M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. EYPT (256M). EYPT has less debt than OCUL: EYPT (21.8M) vs OCUL (76.9M). OCUL has higher revenues than EYPT: OCUL (56.7M) vs EYPT (51.9M).
EYPTOCULEYPT / OCUL
Capitalization1.18B2.5B47%
EBITDA-172.05M-200.5M86%
Gain YTD83.75831.733264%
P/E RatioN/AN/A-
Revenue51.9M56.7M92%
Total Cash256M391M65%
Total Debt21.8M76.9M28%
FUNDAMENTALS RATINGS
EYPT vs OCUL: Fundamental Ratings
EYPT
OCUL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
7092
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3744
P/E GROWTH RATING
1..100
14100
SEASONALITY SCORE
1..100
7524

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (52) in the Pharmaceuticals Other industry is in the same range as EYPT (70) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as OCUL (92) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as EYPT (98) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as OCUL (44) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew similarly to OCUL’s over the last 12 months.

EYPT's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew significantly faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTOCUL
RSI
ODDS (%)
Bearish Trend 6 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 6 days ago
85%
Momentum
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
79%
MACD
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 29 days ago
87%
Bearish Trend 28 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
81%
Bullish Trend 6 days ago
71%
Aroon
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUXFX32.90N/A
N/A
Auxier Focus Inv
IHGIX37.85N/A
N/A
Hartford Dividend and Growth A
SLVRX39.46N/A
N/A
Columbia Select Large Cap Value R
BGVIX37.15N/A
N/A
Brandes Global Equity I
DGFCX30.82N/A
N/A
Davis Global C

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-4.00%
LYRA - EYPT
58%
Loosely correlated
+9.79%
ATHE - EYPT
54%
Loosely correlated
+2.73%
OCUL - EYPT
53%
Loosely correlated
-3.93%
ERAS - EYPT
53%
Loosely correlated
-3.50%
IDYA - EYPT
47%
Loosely correlated
-1.75%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with IDYA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-3.93%
IDYA - OCUL
55%
Loosely correlated
-1.75%
EYPT - OCUL
54%
Loosely correlated
-4.00%
ERAS - OCUL
54%
Loosely correlated
-3.50%
RVMD - OCUL
53%
Loosely correlated
-0.65%
DNLI - OCUL
52%
Loosely correlated
-1.71%
More